Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 21:12:67.
doi: 10.4103/abr.abr_175_21. eCollection 2023.

In Vitro Study of the Leishmanicidal Activity of Perovskia Abrotanoides Terpenoid-Rich Fractions Against Leishmania Major (MRHO/IR/75/ER)

Masoud Sadeghi Dinani  1 , Seyed A Emarati Noushabadi  1 , Fatemeh Namdar  2 , Parastoo Hassani Abharian  3 , S H Hejazi  3 , Zahra Sebghatollahi  3
Affiliations

In Vitro Study of the Leishmanicidal Activity of Perovskia Abrotanoides Terpenoid-Rich Fractions Against Leishmania Major (MRHO/IR/75/ER)

Masoud Sadeghi Dinani et al. Adv Biomed Res. .

Abstract

Background: Cutaneous leishmaniasis (CL) is an ulcerative skin disease caused by some species of the genus Leishmania. Evidence shows that Perovskia abrotanoides is an important herbal medicine against Leishmania. This study was conducted to investigate the killing effect of terpenoid-rich fractions on promastigotes of L. major (MRHO/IR/75/ER).

Material and method: The eluates of reverse phased medium pressure liquid chromatography (RP-MPLC) of the extract were subjected to thin-layer chromatography (TLC) and categorized into six final fractions. Primary proton nuclear magnetic resonance (H-NMR) spectroscopy confirmed fractions' nature. Fractions 4, 5, and 6 (F4, F5, F6) were identified as terpenoid-rich content. Two concentrations of 50 and 100 μg/ml were prepared to test leishmanicidal activity. Followed by treating promastigotes of L. major by the fractions in incubation times of 12, 24, and 48 hours, their viability was determined using a cell proliferation MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay.

Result: F4, F5, and F6 showed significant killing activity on promastigotes of L. major in a concentration-dependent manner. The viability of promastigotes was significantly reduced at a concentration of 100 μg/ml compared to 50 μg/ml (P-value <0.05). Also, over time a significant decreasing trend in the viability of promastigotes confirmed the time-dependent manner of the fractions (P-value <0.01). Furthermore, F5 had the highest leishmanicidal activity at the first incubation time compared with other fractions.

Conclusion: Terpenoid-rich fractions of the P. abrotanoides have a leishmanicidal activity that depends on time and concentration. Among them, F5 has the highest potency that may contain potent terpenoid constituents.

Keywords: In vitro; Leishmania major; leishmanicidal; perovskia abrotanoides; terpenoid-rich fraction.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Mean viability percentage of promastigotes treated with three terpenoid-rich fractions (F4, F5, and F6) at a concentration of 50 μg/ml and at three incubation times (12 h, 24 h, and 48 h)
Figure 2
Figure 2
Mean viability percentage of promastigotes treated with three terpenoid-rich fractions (F4, F5, and F6) at a concentration of 100 μg/ml and at three incubation times (12 h, 24 h, and 48 h)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chanda K. An overview on the therapeutics of neglected infectious diseases—leishmaniasis and chagas diseases. Front Chem. 2021;9:37. - PMC - PubMed
    1. Oladele RO, Ayanlowo OO, Richardson MD, Denning DW. Histoplasmosis in Africa: An emerging or a neglected disease? PLoS Negl Trop Dis. 2018;12:e0006046. - PMC - PubMed
    1. Soosaraei M, Khasseh AA, Fakhar M, Hezarjaribi HZ. A decade bibliometric analysis of global research on leishmaniasis in web of science database. Ann Med Surg. 2018;26:30–7. - PMC - PubMed
    1. Gradoni L. The leishmaniases of the mediterranean region. Curr Trop Med Rep. 2017;4:21–6.
    1. Ponte-Sucre A, Gamarro F, Dujardin J-C, Barrett MP, López-Vélez R, García-Hernández R, et al. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis. 2017;11:e0006052. - PMC - PubMed